These tools will no longer be maintained as of December 31, 2024. Archived website can be found here. PubMed4Hh GitHub repository can be found here. Contact NLM Customer Service if you have questions.


BIOMARKERS

Molecular Biopsy of Human Tumors

- a resource for Precision Medicine *

127 related articles for article (PubMed ID: 1494591)

  • 1. Brofaromine in panic disorder: a pilot study with a new reversible inhibitor of monoamine oxidase-A.
    Garcia-Borreguero D; Lauer CJ; Ozdaglar A; Wiedemann K; Holsboer F; Krieg JC
    Pharmacopsychiatry; 1992 Nov; 25(6):261-4. PubMed ID: 1494591
    [TBL] [Abstract][Full Text] [Related]  

  • 2. Reversible monoamine oxidase-A inhibitors in panic disorder.
    Bakish D; Saxena BM; Bowen R; D'Souza J
    Clin Neuropharmacol; 1993; 16 Suppl 2():S77-82. PubMed ID: 8313401
    [TBL] [Abstract][Full Text] [Related]  

  • 3. MAO inhibitors in panic disorder: clinical effects of treatment with brofaromine. A double blind placebo controlled study.
    van Vliet IM; Westenberg HG; Den Boer JA
    Psychopharmacology (Berl); 1993; 112(4):483-9. PubMed ID: 7871061
    [TBL] [Abstract][Full Text] [Related]  

  • 4. The use of the reversible monoamine oxidase-A inhibitor brofaromine in social phobia complicated by panic disorder with or without agoraphobia.
    Bakish D
    J Clin Psychopharmacol; 1994 Feb; 14(1):74-5. PubMed ID: 8151007
    [No Abstract]   [Full Text] [Related]  

  • 5. Brofaromine (CGP 11 305 A) in treatment of depression: biological estimation of plasma concentrations.
    Fritze J; Becker T; Ziegler V; Laux G; Riederer P
    Pharmacopsychiatry; 1990 May; 23(3):131-4. PubMed ID: 2374771
    [TBL] [Abstract][Full Text] [Related]  

  • 6. Therapeutic and side-effect profile of a selective and reversible MAO-A inhibitor, brofaromine. Results of dose-finding trials in depressed patients.
    Schiwy W; Heath WR; Delini-Stula A
    J Neural Transm Suppl; 1989; 28():33-44. PubMed ID: 2677240
    [TBL] [Abstract][Full Text] [Related]  

  • 7. Reversible monoamine oxidase-A inhibitors in resistant major depression.
    Nolen WA; Hoencamp E; Bouvy PF; Haffmans PM
    Clin Neuropharmacol; 1993; 16 Suppl 2():S69-76. PubMed ID: 8313400
    [TBL] [Abstract][Full Text] [Related]  

  • 8. Brofaromine in non-endogenous major depressed inpatients--results of a preliminary dose-finding trial versus tranylcypromine.
    Volz HP; Heimann H; Bellaire J; Laux G; Möller HJ
    Pharmacopsychiatry; 1994 Jul; 27(4):152-8. PubMed ID: 7972347
    [TBL] [Abstract][Full Text] [Related]  

  • 9. Brofaromine in depression: a Canadian multicenter placebo trial and a review of standard drug comparative studies.
    Chouinard G; Saxena BM; Nair NP; Kutcher SP; Bakish D; Bradwejn J; Kennedy SH; Sharma V; Remick RA; Kukha-Mohamad SA
    Clin Neuropharmacol; 1993; 16 Suppl 2():S51-4. PubMed ID: 8313397
    [TBL] [Abstract][Full Text] [Related]  

  • 10. Is there a role for selective monoamine oxidase inhibitor therapy in bulimia nervosa? A placebo-controlled trial of brofaromine.
    Kennedy SH; Goldbloom DS; Ralevski E; Davis C; D'Souza JD; Lofchy J
    J Clin Psychopharmacol; 1993 Dec; 13(6):415-22. PubMed ID: 8120155
    [TBL] [Abstract][Full Text] [Related]  

  • 11. Reversible monoamine-A inhibitors in panic disorder.
    Bakish D
    Clin Neuropharmacol; 1992; 15 Suppl 1 Pt A():432A-433A. PubMed ID: 1498904
    [No Abstract]   [Full Text] [Related]  

  • 12. A double-blind study of the efficacy of venlafaxine extended-release, paroxetine, and placebo in the treatment of panic disorder.
    Pollack MH; Lepola U; Koponen H; Simon NM; Worthington JJ; Emilien G; Tzanis E; Salinas E; Whitaker T; Gao B
    Depress Anxiety; 2007; 24(1):1-14. PubMed ID: 16894619
    [TBL] [Abstract][Full Text] [Related]  

  • 13. Reversible monoamine oxidase-A inhibitors in social phobia.
    Liebowitz MR; Schneier F; Gitow A; Feerick J
    Clin Neuropharmacol; 1993; 16 Suppl 2():S83-8. PubMed ID: 8313403
    [TBL] [Abstract][Full Text] [Related]  

  • 14. Monoamine oxidase, monoamine oxidase inhibitors, and panic disorder.
    Norman TR; Burrows GD
    J Neural Transm Suppl; 1989; 28():53-63. PubMed ID: 2677243
    [TBL] [Abstract][Full Text] [Related]  

  • 15. Brofaromine--a selective, reversible, and short-acting MAO-A inhibitor: review of the pharmacological and clinical findings.
    Möller HJ; Wendt G; Waldmeier P
    Pharmacopsychiatry; 1991 Mar; 24(2):50-4. PubMed ID: 1852792
    [TBL] [Abstract][Full Text] [Related]  

  • 16. An open trial of fluvoxamine therapy for panic disorder complicated by depression.
    Spiegel DA; Saeed SA; Bruce TJ
    J Clin Psychiatry; 1996; 57 Suppl 8():37-40; discussion 40-1. PubMed ID: 8698679
    [TBL] [Abstract][Full Text] [Related]  

  • 17. Clinical, biochemical and psychometric findings with the new MAO-A-inhibitors moclobemide and brofaromine in patients with major depressive disorder.
    Laux G; Classen W; Sofic E; Becker T; Riederer P; Lesch KP; Struck M; Beckmann H
    J Neural Transm Suppl; 1990; 32():189-95. PubMed ID: 2089089
    [TBL] [Abstract][Full Text] [Related]  

  • 18. Differential response patterns to MAO inhibitors and tricyclics.
    Nies A
    J Clin Psychiatry; 1984 Jul; 45(7 Pt 2):70-7. PubMed ID: 6376487
    [TBL] [Abstract][Full Text] [Related]  

  • 19. Adinazolam-SR in panic disorder with agoraphobia: relationship of daily dose to efficacy.
    Carter CS; Fawcett J; Hertzman M; Papp LA; Jones W; Patterson WM; Swinson RP; Weise CC; Maddock RJ; Denahan AQ
    J Clin Psychiatry; 1995 May; 56(5):202-10. PubMed ID: 7737960
    [TBL] [Abstract][Full Text] [Related]  

  • 20. Personality traits in social phobia, II: Changes during drug treatment.
    Fahlén T
    J Clin Psychiatry; 1995 Dec; 56(12):569-73. PubMed ID: 8530333
    [TBL] [Abstract][Full Text] [Related]  

    [Next]    [New Search]
    of 7.